Trandolapril — $0 on Listed Strengths

Other medications in Heart & Cardiovascular

• Treprostinil
• Triamterene
• Valsartan
• Verapamil
• Verapamil IV
• Vernakalant
• Vorapaxar
• Warfarin

About Trandolapril

Trandolapril is a vital medication often prescribed to manage high blood pressure and certain heart conditions. At TheDrugClub, we understand that managing chronic conditions requires consistent access to necessary medications. We're dedicated to helping our members navigate the costs of prescriptions like trandolapril, ensuring you can prioritize your health without financial strain.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Trandolapril is approved for (FDA label)

Hypertension Trandolapril tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial ).

Source: Read the full FDA label on DailyMed. Label effective date: October 31, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Trandolapril (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue trandolapril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (See WARNINGS : Fetal Toxicity ) .

Source: FDA prescribing information (DailyMed). Set ID: 8143a6cf-dadc-4ef7-a8db-d16d7150ad34. SPL document ID: 97cefaf3-9c1f-43e3-a30c-e9631872a8e8. Label effective date: October 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Trandolapril (FDA label)

The safety experience in U.S. placebo-controlled trials included 1069 hypertensive patients, of whom 832 received trandolapril tablets. Nearly 200 hypertensive patients received trandolapril tablets for over one year in open-label trials. In controlled trials, withdrawals for adverse events were 2.1% on placebo and 1.4% on trandolapril tablets. Adverse events considered at least possibly related to treatment occurring in 1% of trandolapril tablets-treated patients and more common on trandolapril tablets than placebo, pooled for all doses, are shown below, together with the frequency of discontinuation of treatment because of these events.

Source: FDA prescribing information (DailyMed). Set ID: 8143a6cf-dadc-4ef7-a8db-d16d7150ad34. SPL document ID: 97cefaf3-9c1f-43e3-a30c-e9631872a8e8. Label effective date: October 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Trandolapril (FDA label)

Trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Do not co-administer aliskiren with trandolapril tablets in patients with diabetes (see PRECAUTIONS , Drug Interactions). Trandolapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer trandolapril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 8143a6cf-dadc-4ef7-a8db-d16d7150ad34. SPL document ID: 97cefaf3-9c1f-43e3-a30c-e9631872a8e8. Label effective date: October 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Trandolapril (FDA label)

Trandolapril did not affect the plasma concentration (pre-dose and 2 hours post-dose) of oral digoxin (0.25 mg). Coadministration of trandolapril and cimetidine led to an increase of about 44% in C max for trandolapril, but no difference in the pharmacokinetics of trandolaprilat or in ACE inhibition. Coadministration of trandolapril and furosemide led to an increase of about 25% in the renal clearance of trandolaprilat, but no effect was seen on the pharmacokinetics of furosemide or trandolaprilat or on ACE inhibition. Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors.

Source: FDA prescribing information (DailyMed). Set ID: 8143a6cf-dadc-4ef7-a8db-d16d7150ad34. SPL document ID: 97cefaf3-9c1f-43e3-a30c-e9631872a8e8. Label effective date: October 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.